Abstract: The present invention provides novel canine pol I regulatory nucleic acid sequences useful for the expression of nucleic acid sequences in canine cells such as MDCK cells. The invention further provides expression vectors and cells comprising such nucleic acids as well as methods of using such nucleic acids to make influenza viruses, including infectious influenza viruses.
Type:
Application
Filed:
August 31, 2012
Publication date:
December 27, 2012
Applicant:
MedImmune, LLC
Inventors:
Gregory Duke, George Kemble, James Young, Zhaoti Wang
Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
Type:
Grant
Filed:
December 16, 2011
Date of Patent:
December 18, 2012
Assignee:
Medimmune, LLC
Inventors:
Chin-Fen Yang, George Kemble, Chongguang Liu
Abstract: The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant respiratory syncytial viral vectors and viruses are engineered to contain complete deletions of the M2-2, NS1, NS2, or SH viral accessory genes or various combinations thereof. In addition, the present invention relates to the attenuation of respiratory syncytial virus by mutagenisis of the M2-1 gene.
Type:
Application
Filed:
June 5, 2012
Publication date:
December 6, 2012
Applicant:
MedImmune, LLC
Inventors:
Hong Jin, Roderick Tang, Shengqiang Li, Martin Bryant, David Kirkwood Clarke, Peter Palese
Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
Type:
Grant
Filed:
July 27, 2011
Date of Patent:
December 4, 2012
Assignees:
MedImmune, LLC, Board of Regents, The University of Texas System
Inventors:
William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward
Abstract: The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.
Type:
Grant
Filed:
September 7, 2007
Date of Patent:
December 4, 2012
Assignee:
MedImmune, LLC
Inventors:
Melissa Damschroder, Peter Kiener, Herren Wu, William Dall'Acqua, Ronald Herbst, Anthony Coyle
Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
Type:
Application
Filed:
June 29, 2012
Publication date:
November 29, 2012
Applicant:
MEDIMMUNE, LLC
Inventors:
Chin-Fen Yang, George Kemble, Chongguang Liu
Abstract: Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. Additionally, the invention provides methods of producing influenza viruses with enhanced ability to replicate in embryonated chicken eggs and/or cells (e.g., Vero and/or MDCK) and further provides influenza viruses with enhanced replication characteristics. A method of producing a cold adapted (ca) influenza virus that replicates efficiently at, e.g., 25° C. (and immunogenic compositions comprising the same) is also provided.
Type:
Application
Filed:
November 15, 2011
Publication date:
November 15, 2012
Applicant:
MEDIMMUNE, LLC
Inventors:
Erich Hoffmann, Hong Jin, George Kemble, Zhongying Chen
Abstract: The invention provides method for therapeutic protein drug development that incorporates therapeutic and/or formulation and/or manufacturing considerations in the early screening process. The approach involves screening a plurality of different variants of a domain that have been determined to have the desired therapeutic property to identify one or more variants that have desired therapeutic and/or formulation characteristics, and constructing the full multidomain proteins using the identified domain variants. The present invention also provides a method for determining the shelf life of multidomain proteins in formulations. The method comprises determining a thermal denaturation and/or renaturation curve of a domain of the protein whose unfolding leads to aggregation of the protein in a solution. The method evaluates the shelf life of the multidomain protein based on the denaturation/renaturation curve.
Type:
Grant
Filed:
June 30, 2006
Date of Patent:
November 13, 2012
Assignee:
MedImmune, LLC
Inventors:
Christian Allan, Herren Wu, Jeffrey Swers, William Dall'Acqua
Abstract: Methods and compositions for the optimization and production of refrigerator-temperature stable virus, e.g., influenza, compositions are provided. Formulations and immunogenic compositions comprising refrigerator-temperature stable virus compositions are provided.
Type:
Application
Filed:
July 18, 2012
Publication date:
November 8, 2012
Applicant:
MEDIMMUNE, LLC
Inventors:
George Kemble, George Trager, Richard Schwartz
Abstract: Without limitation, this disclosure relates to compositions and methods for detecting and quantifying the expression of insulin receptor isoform A (IR-A) and/or insulin receptor isoform B (IR-B) in a tissue sample. The disclosure also relates to methods of diagnosis and classification based at least in part upon detecting and quantifying the expression of insulin receptor isoform A (IR-A) and/or insulin B (IR-B) in a tissue sample. Methods of treating a subject based upon such a classification are among additional aspects of the disclosure presented herein.
Type:
Application
Filed:
October 11, 2010
Publication date:
November 8, 2012
Applicant:
MEDIMMUNE, LLC
Inventors:
Jiaqi Huang, Chris Morehouse, Katie Streicher, Brandon W. Higgs, Yihong Yao, Theresa Lavalle
Abstract: The present invention provides methods for preventing, managing, treating and/or ameliorating a respiratory syncytial virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and/or lower respiratory tract infection (LRI)), and/or a symptom or a long-term respiratory condition relating thereto (e.g., asthma, wheezing, reactive airway disease (RAD), or chronic obstructive pulmonary disease (COPD)) in a human subject, comprising topically administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and/or high avidity and further comprise a modified IgG constant domain, or FcRn-binding fragment thereof, to not only decrease RSV infection, but also decrease the pro-inflammatory epithelial cell immune responses in order to mitigate the later development of asthma and/or wheezing and/or COPD in said patient.
Abstract: The complete polynucleotide sequence of the human respiratory syncytial virus subgroup B strain 9320 genome is provided. Proteins encoded by this polynucleotide sequence are also provided. Isolated or recombinant RSV (e.g., attenuated recombinant RSV), nucleic acids, and polypeptides, e.g., comprising mutations in the attachment protein G, are also provided, as are immunogenic compositions comprising such isolated or recombinant RSV, nucleic acids, and polypeptides. Related methods are also described.
Abstract: The present invention provides novel serum-free cell culture medium and methods for cultivating MDCK cells. In particular, non-tumorigenic MDCK cells. The present invention also provides methods for producing influenza viruses (e.g., particularly cold-adapted, and/or temperature sensitive, and/or attenuated influenza viruses) that eliminate the need for a cell culture medium exchange step. The novel medium and methods are useful to grow influenza viruses, in cell culture to high titer. The present invention further provides purification methods for purifying influenza viruses with high overall recovery of live virus and result in levels of host cell DNA (HCD), host cell protein (HCP) and non-specific endonuclease (e.g., Benzonase), which are below the specifications required by regulatory agencies. The immunogenic compositions can be used to actively immunize subjects or to generate antibodies for a variety of uses, including passive immunization and diagnostic immunoassays.
Type:
Application
Filed:
May 16, 2012
Publication date:
October 11, 2012
Applicant:
MEDIMMUNE, LLC
Inventors:
Jonathan LIU, Mark Thompson, Luis J. Maranga, Floro Cataniag, Simon S. Hsu
Abstract: The present disclosure encompasses type-I IFN and IFN?-induced PD marker expression profiles, kits, and methods for identifying such IFN?-induced PD marker expression profiles. The type-I IFN and IFN?-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFN?-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that modulates type 1 interferon activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFN? activity, and in diagnosing or providing a prognosis to patients having IFN?-induced disorders.
Type:
Application
Filed:
September 2, 2010
Publication date:
October 4, 2012
Applicant:
MEDIMMUNE LLC
Inventors:
Brandon Higgs, Wei Zhu, Chris Morehouse, Barbara White, Bahija Jallal, Yihong Yao
Abstract: The present invention provides novel canine pol I regulatory nucleic acid sequences useful for the expression of nucleic acid sequences in canine cells such as MDCK cells. The invention further provides expression vectors and cells comprising such nucleic acids as well as methods of using such nucleic acids to make influenza viruses, including infectious influenza viruses.
Type:
Grant
Filed:
July 23, 2010
Date of Patent:
October 2, 2012
Assignee:
Medimmune, LLC
Inventors:
Gregory Duke, George Kemble, James Young, Zhaoti Wang
Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
Abstract: This invention provides methods and compositions to preserve bioactive materials in a matrix of powder particles. Methods provide high-pressure gas spraying and/or near supercritical spraying of formulations followed by drying in a stream of conditioned gas to form stable powder particles containing bioactive materials.
Abstract: The present invention encompasses auto-antibodies associated with autoimmune disorders. The auto-antibodies may be used, for example, in methods of treating patients, methods of diagnosing patients, methods of monitoring disease progression of patients, and methods of prognosing patients.
Type:
Application
Filed:
November 7, 2011
Publication date:
August 30, 2012
Applicant:
MEDIMMUNE, LLC
Inventors:
Jonathan Zmuda, Christina Strange, Wendy Irene White
Abstract: Fc regions useful for site-specific conjugation to a variety of agents are provided. Methods for the design, preparation, screening, selection and use of such Fc regions are also provided.
Abstract: Methods and compositions for the optimization and production of refrigerator-temperature stable virus, e.g., influenza, compositions are provided. Formulations and immunogenic compositions comprising refrigerator-temperature stable virus compositions are provided.
Type:
Grant
Filed:
June 18, 2009
Date of Patent:
August 21, 2012
Assignee:
Medimmune, LLC
Inventors:
George Kemble, George Trager, Richard Schwartz